atorvastatin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beckwitt, CH; Clark, AM; Marti, JLG; Wells, A | 1 |
| Bakar-Ates, F; Ozkan, E | 1 |
| Baretton, GB; Bauer, T; Benad-Mehner, P; Bornhäuser, M; Ebert, R; Göbel, A; Hadji, P; Hofbauer, LC; Jakob, F; Muders, MH; Rachner, TD; Rauner, M; Schem, C; Thiele, S | 1 |
| Hyder, SM; Liang, Y; Mafuvadze, B | 1 |
4 other study(ies) available for atorvastatin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Atorvastatin facilitates chemotherapy effects in metastatic triple-negative breast cancer.
Topics: Animals; Atorvastatin; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Humans; Liver Neoplasms; Mice; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Atorvastatin induces downregulation of matrix metalloproteinase-2/9 in MDA-MB-231 triple negative breast cancer cells.
Topics: Atorvastatin; Cell Line, Tumor; Down-Regulation; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; RNA, Messenger; Triple Negative Breast Neoplasms | 2022 |
Dickkopf-1 is regulated by the mevalonate pathway in breast cancer.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density Conservation Agents; Bone Neoplasms; cdc42 GTP-Binding Protein; Cell Line, Tumor; Diphosphonates; Female; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; L Cells; Lymphocyte Activation; MCF-7 Cells; Mevalonic Acid; Mice; Osteoblasts; Osteogenesis; Osteoprotegerin; Prenylation; Pyrroles; Rho Factor; RNA Interference; RNA, Small Interfering; Triple Negative Breast Neoplasms; Wnt3A Protein; Zoledronic Acid | 2014 |
Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor.
Topics: Atorvastatin; Benzophenones; Breast Neoplasms; Cell Line, Tumor; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gene Expression Regulation, Neoplastic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intramolecular Transferases; Pyrroles; Real-Time Polymerase Chain Reaction; Receptors, Androgen; RNA, Messenger; Transcriptional Activation; Triple Negative Breast Neoplasms | 2014 |